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Effects on muscle tissue remodeling and
lipid metabolism in muscle tissue from
adult patients with polymyositis or
dermatomyositis treated with
immunosuppressive agents
Ingela Loell1†, Joan Raouf1†, Yi-Wen Chen2, Rongye Shi3, Inger Nennesmo4, Helene Alexanderson5,
Maryam Dastmalchi1, Kanneboyina Nagaraju2, Marina Korotkova1 and Ingrid E. Lundberg1*
Abstract
Background: Polymyositis (PM) and dermatomyositis (DM) are autoimmune muscle diseases, conventionally treated
with high doses of glucocorticoids in combination with immunosuppressive drugs. Treatment is often dissatisfying,
with persisting muscle impairment. We aimed to investigate molecular mechanisms that might contribute to the
persisting muscle impairment despite immunosuppressive treatment in adult patients with PM or DM using gene
expression profiling of repeated muscle biopsies.
Methods: Paired skeletal muscle biopsies from six newly diagnosed adult patients with DM or PM taken before and
after conventional immunosuppressive treatment were examined by gene expression microarray analysis. Selected
genes that displayed changes in expression were analyzed by Western blot. Muscle biopsy sections were evaluated
for inflammation, T lymphocytes (CD3), macrophages (CD68), major histocompatibility complex (MHC) class I
expression and fiber type composition.
Results: After treatment, genes related to immune response and inflammation, including inflammasome pathways
and interferon, were downregulated. This was confirmed at the protein level for AIM-2 and caspase-1 in the
inflammasome pathway. Changes in genes involved in muscle tissue remodeling suggested a negative effect on
muscle regeneration and growth. Gene markers for fast type II fibers were upregulated and fiber composition was
switched towards type II fibers in response to treatment. The expression of genes involved in lipid metabolism was
altered, suggesting a potential lipotoxic effect on muscles of the immunosuppressive treatment.
Conclusion: The anti-inflammatory effect of immunosuppressive treatment was combined with negative effects on
genes involved in muscle tissue remodeling and lipid metabolism, suggesting a negative effect on recovery of
muscle performance which may contribute to persisting muscle impairment in adult patients with DM and PM.
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Background
Polymyositis (PM) and dermatomyositis (DM) are chronic,
idiopathic inflammatory myopathies (IIM) characterized by
proximal muscle weakness. Muscle biopsies reveal signs of in-
flammation including infiltrating T cells, macrophages, cyto-
kines (interleukin (IL)-1) interferons (IFNs)) and upregulated
major histocompatibility complex (MHC) class I expression
in the fibers as well as regenerating and degenerating fibers
[1, 2]. Treatment is based on high doses of glucocorticoids
(GC) often combined with additional immunosuppressive
drugs. The effectiveness of GC in patients with PM or DM
varies between individuals, but is often disappointing and few
recover former muscle performance [3–5]. In addition, side
effects such as osteoporosis, hypertension, insulin resistance
and steroid myopathy are common [6].
GC interact with the glucocorticoid receptor (GR) and
form a complex that is translocated into the cell nucleus
where it regulates target gene actions through transrepres-
sion or transactivation mechanisms [7–9]. It is assumed
that the immunosuppressive and anti-inflammatory effects
of GC are mediated through transrepression, downregu-
lating the expression of pro-inflammatory cytokines such
as IL-1, tumor necrosis factor (TNF) and IFNγ [9]. On the
other hand, transactivation through GC response ele-
ments (GREs) controls genes that mediate metabolic
side effects of GC and enhances the expression of anti-
inflammatory genes such as IL-10, IKB and annexin-1
[9]. The limited effects of conventional immunosuppres-
sive treatment, including high doses of GC, on muscle
performance in patients with PM and DM is well recog-
nized, but the underlying molecular mechanisms of the
limited effects have not been completely elucidated.
Persisting upregulation of certain inflammatory pathways
such as infiltrating T cells, MHC-I, several pro-inflammatory
cytokines [10–12], prostaglandin E2 (PGE2) [13] and leuko-
triene B4 (LTB4) pathways [14] in muscle tissue might partly
explain the sustained weakness in patients despite treatment.
Other molecular mechanisms affected by treatment may
also influence muscle performance. This emphasizes the
need for a better understanding of the molecular response
in the target organ (muscle) in order to identify new thera-
peutic targets and abolish the persistent muscle weakness.
In this study, we aimed to investigate molecular events
that might contribute to persisting compromised muscle
function despite immunosuppressive treatment in adult pa-
tients with PM or DM. Thus, we investigated muscle biop-
sies taken before and after conventional immunosuppressive
treatment using gene expression profiling combined with
analysis of selected proteins at the protein level.
Methods
Patients and muscle biopsies
From an observational study, six untreated adult patients
of Caucasian origin diagnosed with probable or definite
DM or PM [15] were all subject to follow-up biopsies
for the study. Disease duration was defined from the first
reported symptom related to disease to time of the first
muscle biopsy. Clinical data including support for diag-
nosis are presented in Table 1. All adult patients were
initially treated with oral prednisolone (0.75 mg/kg/day)
in combination with an additional immunosuppressive
drug (methotrexate or azathioprine) as decided by the
treating physician. Muscle tissue biopsies were taken
from m. vastus lateralis; a repeated biopsy was taken
after 9 months (range 8–15 months) of conventional im-
munosuppressive treatment [16]. None of the patients
exercised at the time of the first biopsy, but all were
instructed to a 5-days-a-week home exercise program
after introduction of glucocorticoids. Patients one, two,
four, and five exercised regularly with the home exercise
program or more intensive gym training 1–2 times a
week during the study period. The regional ethics com-
mittee in Stockholm granted approval (approval number:
2005/792-31/4) and all participants gave informed con-
sent to participate in the study.
Clinical and laboratory assessment
Clinical and laboratory outcome measures were retrieved
from the SweMyoNet quality of care register for myositis
patients and from medical records. Muscle perform-
ance before and after treatment was assessed by the
Manual Muscle Test (MMT-8) and the Functional
Index-2 (FI-2); ≥15 % increase was defined as improved
[17]. The MMT-8 measures isometric muscle strength
in eight muscle groups [18] and the FI-2 measures dy-
namic repetitive muscle performance; it includes seven
muscle groups with a maximum of 60 or 120 repetitions
for each muscle [19]. Both the MMT-8 and the FI-2 are
presented as % of maximal score (100 % = good muscle
performance) in Table 1. Serum levels of creatine kinase
(CK) and lactate dehydrogenase (LD) were analyzed as
routine tests at the Department of Clinical Chemistry,
Karolinska University Hospital. Myositis-associated and
myositis-specific autoantibodies were tested by RNA
immunoprecipitation (IP) and protein IP in Kyoto, Japan,
and are presented in Table 1 [20, 21].
Histopathological and immunohistochemical analyses
Histopathological evaluation of muscle tissue sections
was performed by an experienced muscle pathologist
on coded sections stained with hematoxylin and eosin.
Immunohistochemistry staining was used to identify the
presence of inflammatory cells such as T lymphocytes
(CD3), macrophages (CD68) and the expression of MHC
class I according to a standard protocol [22] using mouse
monoclonal anti-CD3 (BD Biosciences, CA, USA), anti-
CD68 (Dako Cytomation, Denmark) and anti-MHC-I
(My Bio Sourse, CA, USA) antibodies. Isotype-matched
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Table 1 Clinical data on the patients at the time of biopsies
Patient
ID
Diagnosis Age
(years)
Gender Disease
duration
(months)
Cumulative
cortisone (mg)
Imuunosuppressive
treatment at
second biopsy
Autoantibodies Support for
diagnosis
MMT-8 (%) s-CK (μcat/L) HAQ (0.0–3.0) FI-2 (%)
B A B A B A B A
1 DM 40 M 3 14450.0 Pred, AZA MDA5, SSA,
Ro60
MW, S, LD 87.5 87.5 1.3 1.1 1.13 0.75 21.7 27.4
2 PM 73 F 12 6222.5 Pred, MTX Neg MW, CK, MB 85.0 85.0 10.2 1.5 0.5 0.88 18.3 19.1
3 DM 69 F 2 10017.5 Pred, MTX ANA, TIF1γ MW, CK, S,
EMG
81.4 91.3 29.3 1.0 0.63 0 0 11.2
4 DM 63 M 0.5 7330.0 Pred, AZA Neg MW, CK, S,
EMG
78.8 90.0 48.2 1.0 0,38 0 86.2 100.0
5 DM 45 F 16 6842.5 Pred, MTX ANA, Mi-2 MW, CK, MB,
S, EMG
98.8 87.5 43.0 2.1 1.5 0.88 17.3 25.3
6 PM 71 F 12 8415.0 Pred, AZA Neg MW, CK, MB 75.7 100 9.0 3.9 1.25 1.88 NA 17
A after treatment, ANA antinuclear antibodies, AZA azathioprine, B before treatment, CK creatine kinase (reference interval, male: 3.3 μkat/L, female: 2.5 μkat/L), DM dermatomyositis, EMG positive for electromyography,
F female, FI-2 Functional Index-2 (0–100 %; impairment in performing repetitions, respective no impairment), HAQ Health Assessment Questionnaire (0.00–3.00; no impairment, respective impairment), LD lactate
dehydrogenase (reference interval 105–333 IU/L), M male, MB positive muscle biopsy, MDA5 melanoma differentiation-associated protein 5, MMT-8 manual muscle testing in 8 muscle groups (0–100 %; muscle strength), MTX
methotrexate, MW muscle weakness, NA not available, PM polymyositis, Pred prednisone, S skin rash, s-CK serum creatine kinase, SSA anti-Sjögren’s syndrome-related antigen A (also called anti-Ro), TIF1γ transcription
intermediary factor 1-gamma
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irrelevant antibodies were used as negative controls.
Conventional microscopic evaluation of the staining was
performed and the whole tissue sections were scored for
CD3 and CD68 as follows: 0, no positive cells; 1, few posi-
tive scattered cells or one infiltrate of inflammatory cells; 2,
clusters of positive cells or two infiltrates of inflammatory
cells; and 3, several large cellular infiltrates. For MHC-I
staining, the sections were scored as follows: 0, no positive
fibers; 1, few positive scattered fibers; 2, clusters of positive
fibers; and 3, several large areas with positive fibers.
Fiber-type composition was determined by mATPase
staining to distinguish between slow-twitch type I and
fast-twitch type II muscle fibers [23, 24]. In brief, muscle
sections were pre-incubated at acidic or alkaline pH, re-
spectively. Type I fibers emerge in a black color at pH 4.3
in contrast to type II fibers which appears in white; the
opposite pattern is observed when pre-incubating at
pH 10.3. Semi-quantitative analysis was applied on coded
sections for analysis of fiber-type composition; the whole
tissue section area was evaluated by counting fibers using
a Leica microscope system (BX60; digital camera, Sony
CDK-500, Tokyo, Japan). The results are presented as fiber
type percentage of the total amount of fibers on the
section.
RNA expression profiling
Expression profiling was performed using Affymetrix
Human Genome U133 Plus 2.0 microarrays. Total RNA
isolation, cDNA synthesis, cRNA labeling, microarray
hybridization, and image acquisition were performed
according to the manufacturer’s protocol [25]. The
quality control criteria developed at the Children’s Na-
tional Medical Center Microarray Center for each array
were followed [25].
Hybridization signals of the microarrays were recorded
using Microarray Suite 5.0 (MAS 5.0) (Affymetrix) and
the data were analyzed using GeneSpring 7.0 (Agilent,
CA, USA). Genes were filtered with the number of present
calls across the 12 arrays analyzed. Genes with at least one
present call were selected for statistical analysis using
paired t test. All profiles have been made publicly access-
ible via NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/).
Genes with a fold change ≥2 were selected, and a func-
tional analysis of the molecular networks and pathways
was performed using the Ingenuity Pathway Analysis
(IPA; Ingenuity Systems®, www.ingenuity.com). The sig-
nificance of the association between the genes in the data-
set, biological functions, and pathways was determined by
the right-tailed Fischer’s exact test.
Western blot
Western blot was performed by using a tissue section
protocol [26]. The 10-μm muscle sections were lysed in
Tissue Protein Extraction Reagent (T-PER; Thermo
Scientifics, USA) supplemented with 1× complete pro-
tease inhibitor cocktail (Roche Diagnostics GmbH,
Mannheim, Germany) and incubated on ice for 30 min.
The protein content was determined using a Bio-Rad
protein assay (Bio-Rad Laboratories AB, Sweden). Gel
electrophoresis was carried out on the NuPAGE® Novex®
Bis-Tris gel system (Invitrogen AB, Sweden). Proteins
were transferred on a polyvinylidene difluoride membrane
using a Trans-Blot SD semi-dry transfer cell (Bio-Rad La-
boratories). The membrane was blocked with 5 % milk in
phosphate-buffered saline (PBS; 0.1 % Tween-20) and in-
cubated with primary (rabbit polyclonal anti-caspase-1
(Millipore, MA, USA), rabbit polyclonal anti-FKBP5
(Millipore, MA, USA), mouse monoclonal anti-AIM-2
(LifeSpan Biosciences, WA, USA)) (overnight, 4 °C) and
secondary (ECL anti-mouse IgG HRP linked (GE Health-
care, UK), ECL anti-rabbit IgG HRP linked (GE Health-
care, UK)) (1 h, room temperature) antibodies. The bands
were detected by enhanced chemiluminescence (ECL)
and the band intensities were measured using the Gel
Doc XR system (Bio-Rad Laboratories). Quantification
was performed with normalization against GAPDH as a
housekeeping protein.
Statistical analyses
Clinical and experimental data were analyzed using
Wilcoxon signed rank test. The level of significance was
set at a p value ≤0.05.
Results
Effects of treatment on clinical parameters
Clinical data are summarized in Table 1. All untreated
patients had a median of 7.5 months (range 0.5–16 months)
duration of clinical symptoms to the first biopsy, which was
taken as part of the diagnostic work-up. At the time of the
second biopsy, after a median of 9 months (range 8–15
months) with immunosuppressive treatment, two out of six
adult patients fulfilled the definition of improvement for
MMT-8, and four patients improved for FI-2. One out of
the six patients achieved the maximum score of 100 % but
still had a low test on endurance FI-2, and only one reached
the maximum test of FI-2 at the second biopsy, indicating
persisting muscle impartment in almost all patients (Table 1).
All patients had normal CK values at the second biopsy
(Table 1).
Histopathological and immunohistochemical changes in
pre- and post- treatment muscle biopsies
In the pre-treatment biopsy, four patients had detectable
inflammatory cells: two had large inflammatory infiltrates,
and two had scattered T lymphocytes or macrophages.
Five out of the six patients had detectable positive staining
for MHC-I expression in muscle fiber membranes, ran-
ging from small areas with discrete staining to large areas
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with whole fibers expressing MHC-I. In the follow-up
biopsy after immunosuppressive treatment, a few scat-
tered T lymphocytes and macrophages were present in
one patient, and scattered T lymphocytes were found in
another patient. MHC class I expression was expressed
in muscle fibers in one of five available follow-up biop-
sies. In addition, two pre-treatment biopsies showed
signs of degenerating or regenerating fibers, but none
of the follow-up biopsies showed this.
Effects of treatment on the overall gene expression
After treatment, the expression of 369 genes was signifi-
cantly affected (>2.0 fold change) in the muscle tissue of
patients, including 126 upregulated and 243 downregu-
lated genes. Gene Ontology analysis demonstrated that
the top Upstream Regulators statistically relevant for our
gene dataset were Interferon Gamma (IFNG), interferon
regulatory factor 7 (IRF7), Interferon type I (IFNα), signal
transducer and activator of transcription 2 (STAT2) and
Interferon Alfa 2 (IFNA2), which were predicted to be
inhibited based on the gene expression changes in the
dataset.
Effects on genes associated with immune response and
inflammation
Gene Ontology analysis showed that the expression of 39
out of 43 genes associated with immune response and in-
flammation was downregulated by treatment (Table 2).
Among the downregulated genes, a high representation of
HLA-genes encoding MHC-I and MHC-II (which present
antigens to CD8+ and CD4+ T cells, respectively) was seen.
The expression of the co-stimulatory molecules CD80 and
CD86 was also reduced. Moreover, a variety of chemokine
receptors and ligands, both α- and β-chemokines, were
downregulated (Table 2). Furthermore, the interferon sig-
naling pathway was strongly downregulated in response to
treatment. The expression of 13 genes, which are involved
in type I as well as in type II IFN signaling, was reduced
(Table 2, Fig. 1). Moreover, Absent in melanoma 2 (AIM2)
and Caspase-1 (CASP1), components of an inflamma-
some complex promoting inflammation, were also down-
regulated. Additionally, specific receptors for pro-
inflammatory lipid mediators such as Prostaglandin E
Receptor 4 (PTGER4) and Cysteinyl Leukotriene Recep-
tor 1 (CYSLTR1) were downregulated by treatment.
Effects on genes involved in muscle tissue remodeling
A number of genes associated with muscle tissue remod-
eling were affected by treatment (Table 3). Five genes as-
sociated with the ubiquitin-proteasome pathway were
downregulated. The GR co-chaperone protein FK506
binding protein 5 (FKBP5) was upregulated while Nuclear
receptor co-activator 6 (NCOA6) was decreased after
treatment. The expression of the genes for sarcomeric
muscle protein α-actinin 3 (ACTN3) and vinculin (VCL)
was enhanced, suggesting a compensatory increase to
cope with the muscle loss due to degeneration. How-
ever, the negative regulator of muscle growth Myostatin
(MSTN) was also upregulated suggesting active inhib-
ition of muscle growth, while Bone morphologic protein
1 (BMP1) protease that can regulate MSTN by cleaving
was downregulated after treatment. Also, Ras associated
with diabetes (RRAD) and Myosin binding protein H
(MYBPH) that is involved early in skeletal muscle de-
velopment was suppressed upon treatment suggesting
reduced fiber regeneration. IPA functional analysis
based on over-representation and expression direction
of genes in our data set predicted the size of muscle
cells and development of blood vessels to be reduced after
treatment (Z-score –2.108 and –2.509, respectively). These
data indicate negative effects of treatment on muscle fiber
differentiation and growth. In addition, the expression of
the myosin heavy chain 4 (MYH4) and ACTN3, specific
markers for fast type II fibers, was upregulated suggesting
a fiber type switch towards fast type II fibers in response to
treatment.
Effects on genes involved in lipid metabolism
Treatment resulted in significant changes in the expres-
sion of genes involved in lipid metabolism (Table 4).
Genes responsible for fatty acid (FA) uptake and trans-
port such as fatty acid binding protein 7 (FABP7) and
ATP-binding cassette, sub-family D member 2 (ABCD2)
were upregulated. Moreover, genes that promote lipoly-
sis such as Lipoprotein Lipase (LPL), Hormone-sensitive
lipase (LIPE), and Carboxylesterase 1 (CES1) were also
upregulated, while the genes that protect from lipolysis,
for instance Lipid Storage Droplet Protein (LSDP5), were
suppressed suggesting enhanced generation of free FA.
Genes associated with FA oxidation and oxidative phos-
phorylation was not affected (data not shown), suggest-
ing partition of FA into intramuscular lipids. Moreover,
genes that favor lipogenesis and lipid storage, e.g. stear-
oyl-CoA desaturase (delta-9) (SCD), cell death-inducing
DFFA-like effector c (CIDEC), and ceramide synthase 3
(CERS3), were enhanced (Table 4). In line with these
results, based on expression results of genes in the
data set, storage of lipids was predicted to be increased
(Z-score +2.066). Notably, the expression of sphingosine
kinase 1 (SPHK1) was decreased, suggesting enhanced
accumulation of ceramide, an important lipid mediator
previously implicated in lipotoxicity [27].
Confirmation of changes at the protein level
To confirm changes in gene expression at the protein level
by Western blot we selected eight genes that were signifi-
cantly changed. Two of the chosen genes are involved in
the inflammatory pathway (AIM-2 and Caspase-1), which
Loell et al. Arthritis Research & Therapy  (2016) 18:136 Page 5 of 13
Table 2 Changes in expression (cutoff 2-fold) of the genes involved in immune responses and inflammation in patients with
polymyositis or dermatomyositis after a median of 8.5 months of immunosuppressive treatment
Gene symbol Gene Affy # Fold change p
Immune response and antigen presentation
CCL2 chemokine (C-C motif ) ligand 2 216598_s_at –5.9 0.004
CCL5 chemokine (C-C motif ) ligand 5 1405_i_at –3.0 0.043
CCR2 chemokine (C-C motif ) receptor 2 206978_at –2.3 0.004
CCR5 chemokine (C-C motif ) receptor 5 206991_s_at –2.8 0.027
CD52 CDW52 antigen (CAMPATH-1 antigen) 204661_at –2.7 0.037
CD80 CD80 antigen (CD28 ag ligand 1, B7-1 ag) 1554519_at –2.2 0.034
CD86 CD86 antigen (CD28 ag ligand 2, B7-2 ag) 210895_s_at –2.6 0.013
CHRNA1 cholinergic receptor, nicotinic, αpolypeptide 1 206633_at –2.8 0.028
CNPY3 trinucleotide repeat containing 5 1556389_at –2.1 0.022
CPM carboxypeptidase M 206100_at 2.2 0.028
HLA-DQB1 MHC class II, DQβ2 212998_x_at –2.0 0.033
HLA-A major histocompatibility complex, class I, A 215313_x_at –2.2 0.012
HLA-G HLA-G histocompatibility antigen, class I, G 211530_x_at –2.3 0.010
HLA-C MHC class I, C 208812_x_at –2.2 0.013
HLA-B MHC class I, B 209140_x_at –2.2 0.017
HLA-F MHC class I, F 204806_x_at –2.6 0.018
HLA-DQA1 MHC class II, DQα1 203290_at –2.6 0.036
HLA-DQB1 MHC class II, DQβ1 209823_x_at –2.8 0.010
HLA-DPA1 MHC class II, DPα1 213537_at –2.9 0.009
IL-23A Interleukin 23, subunit alpha 217328_at –5.2 0.005
IL-12RB1 Interleukin 12 receptor, beta 1 1552584_at –2.1 0.020
NMU Neuromedin U 206023_at 2.8 0.028
MMP3 Matrix metalloproteinase 3 205828_at 10.7 0.023
IFN pathway
STAT1 signal transducer & activator of transcription 1, 91 kDa 209969_s_at –3.3 0.008
CXCL10 chemokine (C-X-C motif ) ligand 10 204533_at –5.6 0.020
CXCL11 chemokine (C-X-C motif ) ligand 11 211122_s_at –5.6 0.015
RTP4 28kD interferon responsive protein 219684_at –5.7 0.028
IRF8 IFN consensus sequence binding protein 1 204057_at –2.4 0.033
ISG20 IFN stimulated gene 20 kDa 204698_at –5.8 0.029
IFI6 IFNα-inducible protein 204415_at –4.7 0.045
IFI30 IFNγ-inducible protein 30 201422_at –2.2 0.036
IFI35 IFN -induced protein 35 209417_s_at –2.6 0.036
IFIT3 IFN -induced protein w tetratricopeptide repeats 4 229450_at –5.1 0.032
IRF9 IFN -stimulated transcription factor 3, γ 203882_at –3.8 0.005
GBP1 guanylate binding protein 1, IFN-inducible 202269_x_at –2.9 0.009
GBP2 guanylate binding protein 1, IFN-inducible 242907_at –2.7 0.005
GBP5 guanylate binding protein 5 238581_at –2.1 0.017
Inflammasome
AIM2 absent in melanoma 2 206513_at –2.5 0.008
CASP1 caspase 1, (interleukin 1β convertase) 211367_s_at –2.3 0.009
IL18 interleukin 18 (IFNg-inducing factor) 206295_at –2.2 0.042
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were both downregulated after treatment. The FKBP5
gene is implicated in muscle tissue remodeling and was
upregulated after treatment. Using Western blot, we
confirmed significantly reduced protein expression of
AIM-2 and Caspase-1 (p < 0.05), suggesting a reduction
in inflammatory signaling (Fig. 2). We also observed an
increased protein expression of FKBP5 (p < 0.05), sup-
porting a negative effect on muscle tissue remodeling
by the immunosuppressive treatment. No significant
changes for EP3, EP4, CystLTR1, FOXO1A, and FABP7
were detected at the protein level (data not shown).
Effects on fiber type composition
A switch in fiber types was seen in the post-treatment
biopsy as compared to that before treatment. The per-
centage of type I fibers had decreased significantly after
treatment, from a median of 52 % (range 31–57 %) to
43 % (range 14–46 %) (p < 0.05). In contrast, the propor-
tion of type II fibers was significantly higher after treat-
ment (before treatment, median 48 % (range 43–69 %);
after treatment, 57 % (54–86 %); p < 0.05), thus confirm-
ing the gene expression data (Fig. 3).
Discussion
In the present study, in which adult patients improved
but none had recovered muscle strength at the follow-
up biopsy, we found that immunosuppressive treatment
of newly diagnosed PM and DM patients had suppressive
effects on gene expression of immune and inflammatory
pathways, including type 1 IFN and inflammasome path-
ways, in skeletal muscle. However, we also observed chan-
ged expression of genes involved in skeletal muscle tissue
remodeling indicating protein breakdown and reduced
muscle regeneration, which may negatively affect muscle
Table 2 Changes in expression (cutoff 2-fold) of the genes involved in immune responses and inflammation in patients with
polymyositis or dermatomyositis after a median of 8.5 months of immunosuppressive treatment (Continued)
Eicosanoids
PTGER3 prostaglandin E receptor 3 (subtype EP3) 210832_x_at 3.0 0.013
PTGER4 prostaglandin E receptor 4 (subtype EP4) 204897_at –2.0 0.027
CYSLTR1 cysteinyl leukotriene receptor 1 230866_at –2.8 0.037
Fig. 1 Schematic diagram illustrating the suppression of the interferon (IFN) pathway in the skeletal muscle of patients with PM or DM after
immunosuppressive treatment determined using the Ingenuity Pathways Analysis knowledge database. Green represents significant downregulation of
the gene expression, red implies significant upregulation, and grey specifies changes that did not reach the defined cutoff. A higher intensity of the
colors suggests a higher degree of change. No color indicates no presence of this particular gene in our data set
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Table 3 Changes in expression (cutoff 2-fold) of genes involved in ubiquitin proteasome pathway, skeletal muscle structure, and
remodeling in patients with polymyositis or dermatomyositis after immunosuppressive treatment
Gene symbol Gene Affy # Fold change p
Ubiquitin proteasome pathway
PSMB8 proteasome subunit,β type, 8 (large multifunctional protease 7) 209040_s_at –6.6 0.003
UBE2L6 ubiquitin-conjugating enzyme E2L 6 201649_at –2.8 0.032
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 204279_at –2.4 0.005
PSME1 proteasome) activator subunit 1 (PA28 α) 200814_at –2.3 0.007
PSME2 proteasome activator subunit 2 (PA28β) 201762_s_at –2.0 0.012
CNTN3 ubiquitin-activating enzyme E1C (UBA3 homolog, yeast) 229831_at 2.4 0.029
Structure proteins and tissue remodeling
MYBPH myosin binding protein H 206304_at –6.9 0.036
RRAD Ras-related associated with diabetes 204803_s_at –3.2 0.013
BMP1 bone morphogenetic protein 1 207595_s_at –2.7 0.001
NCOA6 Nuclear receptor co-activator 1568874_at –3.0 0.041
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit 1555993_at –2.9 0.035
CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 226368_at –2.1 0.009
MYH4 myosin, heavy polypeptide 4, skeletal muscle 208148_at 2.2 0.020
FOXO1 forkhead box O1A 202723_s_at 2.3 0.026
MSTN growth differentiation factor 8 207145_at 2.3 0.041
VCL vinculin 200930_s_at 2.4 0.022
TIMP4 tissue inhibitor of metalloproteinase 4 206243_at 2.6 0.024
FKBP5 FK506 binding protein 5 204560_at 3.4 0.015
ACTN3 actinin, alpha 3 206891_at 3.4 0.037
Table 4 Changes in expression of the genes involved in lipid metabolism in patients with polymyositis or dermatomyositis after
immunosuppressive treatment
Gene symbol Gene Affy # Fold change p
Lipid transport and uptake
FABP7 fatty acid binding protein 7, brain 205029_s_at 10.0 0.002
ABCD2 ATP-binding cassette, sub-family D member 2 207583_at 4.55 0.043
APOL6 apolipoprotein L, 6 241869_at –3.12 3.14E-05
Lipid accumulation and lipolysis
SCD stearoyl-CoA desaturase (delta-9) 223839_s_at 3.86 0.042
CIDEC cell death-inducing DFFA-like effector c 219398_at 3.53 0.049
CERS3 ceramide synthase 3 1554252_a_at 3.2 0.021
CES1 carboxylesterase 1 209616_s_at 2.98 0.028
MSTN myostatin 207145_at 2.28 0.041
CNR1 Human CB1 cannabinoid receptor 213436_at 2.14 0.009
LPL lipoprotein lipase 203549_s_at 2.05 0.022
LIPE lipase, hormone-sensitive 213855_s_at 2.00 0.034
ACSL3 fatty-acid-Coenzyme A ligase, long-chain 3 236168_at –3.87 0.048
LSDP5 Lipid Storage Droplet Protein 5 1560457_x_at –2.61 0.030
SPHK1 sphingosine kinase 1 219257_s_at –2.20 0.037
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regeneration and growth. Furthermore, we found altered
expression of genes associated with lipid uptake, lipolysis,
and lipid accumulation in response to treatment, indicat-
ing complex effects on intramuscular lipid metabolism
that may also have a negative effect on muscle perform-
ance. Among the immune and inflammatory pathways
suppressed by treatment, the downregulation of type I
IFN pathways in muscle tissue was most striking. It is well
recognized that the type I IFN pathway is activated in
patients with autoimmune diseases including IIM [28, 29].
A significant upregulation of IFN-inducible genes in
muscle biopsies from PM and DM patients was detected
compared to age-/sex-matched controls [30, 31]. The high
overexpression of interferon-inducible genes was also
demonstrated in whole blood from both PM and DM pa-
tients [32]. Moreover, a recent study of peripheral blood
gene expression has revealed that IIM patients displayed a
predominant IFNα-mediated response program [29]. The
expression of type I IFN-inducible genes in whole blood
correlated with disease activity in PM and DM patients
and was reduced after immunomodulatory therapies
[32, 33]. Our novel finding that immunosuppressive
treatment suppressed the IFN pathway in muscle tissue
from PM and DM patients is in agreement with these
previous reports. Our results provide additional evi-
dence supporting the beneficial effects of conventional
Fig. 2 FKBP5 was significantly upregulated after glucocorticoid treatment. AIM-2 and Caspase-1 expression was significantly downregulated after
glucocorticoid treatment. a The expression of FKBP5 and GAPDH before (B) and after (A) glucocorticoid treatment was determined by Western blot.
b Densitometry plots showing FKBP5 expression normalized to GAPDH and expressed as fold-increase relative to before sample. c Densitometry plots
showing AIM-2 expression normalized to GAPDH. d Densitometry plots showing Caspase-1 expression normalized to GAPDH. *p < 0.05
Fig. 3 The fiber type composition was significantly different after glucocorticoid treatment. a The percentage of type I fibers was significantly
decreased after glucocorticoid treatment from median 52 % to median 43 % (*p < 0.05). b The proportion of type II fibers was significantly increased
after treatment from median 48 % to median 57 % (*p < 0.05)
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immunosuppressive treatment in myositis, through in-
hibition of the IFN pathway and reduced formation of
pro-inflammatory mediators in muscle tissue.
Another finding was downregulation of genes involved
in inflammasome activity in response to treatment,
which was confirmed at the protein level for AIM-2 and
Caspase-1. Our findings have added insights into the
favorable effects of conventional immunosuppressive
treatment, which includes inhibition of the inflamma-
some pathway in muscle tissue in patients with PM or
DM, as well as several other pathways associated with
immune response and inflammation, which was validated
by immunohistochemistry confirming a low degree of
inflammation in the post-treatment biopsies as assessed
by CD3, CD68, and MHC-I expression.
However, our group has previously demonstrated an
insufficient effect of immunosuppressive treatment on
PGE2 and LTB4 pathways associated with the persistent
expression of mPGES-1, COX-1, and 5-LO proteins in
myositis muscle despite treatment [13, 14]. In line with
these observations, we did not detect any alterations in
the gene expression of these enzymes or changes at the
protein level for the eicosanoid receptors EP3, EP4, and
CysLTR1. The receptors were expressed at the protein
level in muscle from patients with myositis before and
after treatment, suggesting that PGE2 and LT might
contribute to chronic inflammation and muscle wasting
and these pathways could be potential targets for new
therapies.
Importantly we found signs in the gene expression
profiles after treatment indicating an effect on muscle
remodeling. We observed downregulation of several genes
in the ubiquitin-proteasome pathway and also increased
expression of structural proteins such as α-actinin and
vinculin, indicating an increase in muscle mass. Reversely,
we detected increased expression of myostatin, suggesting
inhibition of myogenesis and a negative effect on muscle
growth. Furthermore, downregulation of RRAD and
MYBPH could also be a sign of reduced muscle regen-
eration. RRAD expression was elevated during skeletal
muscle development as well as in adult muscle post-
injury [34]. FKBP5 is an essential functional regulator
of the GR complex and is associated with muscle tissue
alteration; it plays an important role in basic cellular
processes and in immunoregulation involving protein
folding and trafficking [35]. We observed an increased
protein expression of FKBP5, implicating a negative ef-
fect on muscle tissue remodeling. Overall, these data
point to negative effects of conventional immunosup-
pressive treatment on muscle regeneration and growth.
Furthermore, the enhanced gene expression of specific
markers for fast type II fibers, MYH4 and ACTN3, sug-
gest a fiber-type switching towards the type II fibers in
response to treatment, which was confirmed by analysis
of fiber-type composition. This observation is in agree-
ment with the clinical problem of low muscle endurance
as measured by FI-2 and with previous data reporting a
shift towards fast twitch type II fibers in patients with
chronic PM or DM which interestingly could be reversed
by exercise [36, 37].
A third pathway that we found to be altered in muscle
tissue after immunosuppressive treatment relates to lipid
metabolism. The balance between lipid production and
oxidation is essential for normal cell functions; thus, an
excess of FFA is converted to triacylglycerol for intracel-
lular lipid storage. The dysregulation of this process
leads to the production of lipotoxic lipid intermediates
(ceramides, diacylglycerol, fatty acyl CoA) that might
cause cell dysfunction or death [38]. A novel observation
from our study is that immunosuppressive treatment in-
cluding GC might affect lipid storage in skeletal muscle.
In addition, upregulated CERS3 suggests an enhanced
accumulation of ceramide which has previously been
linked to insulin resistance [39]. Moreover, ceramide has
been implicated in skeletal muscle dysfunction and fa-
tigue in chronic diseases and in mouse muscle fibers in
vitro [40, 41]. Additional detailed studies are needed to
define lipid profiles in muscle tissue from myositis pa-
tients in comparison with healthy individuals and in re-
lation to immunosuppressive treatment. Notably,
patients with juvenile DM are at risk of developing
lipodystrophy, associated with loss or redistribution of
subcutaneous fat [42]. The lipodystrophy is accompan-
ied by metabolic abnormalities such as insulin resist-
ance, diabetes and dyslipidemia, and may occur as a
result of inflammation. Our study included adult pa-
tients, although there is very little known about lipody-
strophy in adult patients with PM or DM. There is a
case study from 2007 describing a woman suffering
from a typical DM which developed lipodystrophy and
insulin resistance [43]. Although worth mentioning,
there is no evidence that standard therapies for DM
causes lipodystrophy.
A strength of our study is the paired muscle biopsy
samples, with two biopsies taken from the same individ-
uals and the repeated biopsy that was taken regardless of
clinical signs of a flare. A paired sample study design re-
duces the problem of inter-individual variations. Never-
theless, our current study has several limitations: one of
them is the low number of patients included and the
heterogeneity in diagnoses of PM and DM and in the de-
gree of histopathological changes before treatment. Also,
no magnetic resonance imaging (MRI) was performed
before the biopsies were taken which could have en-
hanced the detection of inflammation in the muscle. Dif-
ferences in typical histopathological features in muscle
biopsies seen in PM and DM suggest that different
mechanisms may contribute to the muscle inflammation.
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However, several studies on cytokine and chemokine
expression have not revealed significant differences be-
tween PM and DM, suggesting that inflammatory mo-
lecular pathways may be shared. One patient with
typical DM features and muscle weakness had no signs
of MHC class expression on muscle fibers, which could
be explained by the sometimes patchy distribution of
MHC class I expression. Another limitation is the in-
consistency in the immunosuppressive treatment used
in combination with GC, as it was given based on the
decision of the treating physician, although all patients
were treated with high doses of GC. Furthermore, the
total expected duration of immunosuppressive treat-
ment in patients with PM or DM is often 2–3 years.
Here, we chose to take a repeated biopsy after approxi-
mately 9 months, which is not likely to show the final
repaired muscle but rather an effect of the immunosup-
pressive treatment on molecular pathways (which was
the aim of our study). Despite the heterogeneity in diagno-
sis and treatment and the low degree of inflammatory cell
infiltrates in two patients before treatment, we could
still see significant downregulation of genes involved in
inflammation, supporting the beneficial effect of the
immunosuppressive treatment on the inflammatory path-
way. One patient developed type 2 diabetes after the start
of immunosuppressive treatment. None of the other pa-
tients had medications or conditions that could impact
muscle metabolism. Furthermore, details on diet were not
included. In recent years, our group has shown that inten-
sive exercise can have a positive influence on muscle
health [44]. Four out of the six patients in the present
study did exercise regularly, which might have counter-
acted some of the damage induced by the oral corticoster-
oid treatment. Moreover, it is not possible to distinguish
between the relative contribution of the disease progress
and the immunosuppressive treatment on the outcome in
this study. To address this question an experimental
model should be considered. Due to the limited number
of patients the results need to be interpreted with some
caution and need to be replicated in a larger cohort of
patients.
Conclusions
In conclusion, a majority of genes involved in immune
response were downregulated in muscle tissue from pa-
tients with PM or DM after conventional immunosup-
pressive treatment. In addition, genes involved in protein
degradation and muscle regeneration were altered, indi-
cating insufficient muscle tissue remodeling, and, finally,
the expression of genes related to lipid metabolism was af-
fected by treatment, suggesting intramuscular lipid accu-
mulation leading to skeletal muscle dysfunction. These
findings provide new plausible explanations for the per-
sistent muscle weakness and fatigue observed in patients
despite treatment, and diminished tissue inflammation,
and at least some of these may be affected in a beneficial
way by combining immunosuppressive treatment with
physical exercise.
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